The delayed launch date is a result of a negotiated intellectual property settlement with AbbVie, according to EndPoints News.
Under the settlement, Hadlima will be the second Humira copycat to enter the U.S. market, after Amgen, but before Mylan and Sandoz release their own biosimilars
Hadlima is manufactured by Samsung Bioepis and is approved to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn’s disease, ulcerative colitis and plaque psoriasis. It contains a black box warning about risks of infection and lymphoma.
More articles on pharmacy:
Oklahoma opioid trial wraps: 10 takeaways
Drugmaker tried to shred records before FDA inspection, agency claims
Publix Pharmacy to deliver prescriptions to patients before hospital discharge
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
